Vir Biotechnology Reports Positive Data in Chronic Hepatitis Delta Trial

MT Newswires Live01-14

Vir Biotechnology (VIR) reported positive data from updated Phase 2 results in chronic hepatitis delta, showing that the combination of its investigational therapies tobevibart and elebsiran was well tolerated.

The company said Monday in a statement that 88% of patients had no detectable hepatitis D virus in their blood at 96 weeks.

Vir said it will present new Phase 1 data for VIR-5500, an experimental prostate-cancer therapy, at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in February.

The company ended 2025 with about $781 million in cash and investments, extending its cash runway into Q4 2027.

Vir said it expects multiple clinical milestones in 2026, including initial topline data from its Phase 3 chronic hepatitis delta program.

Vir shares rose 1.6% in recent Tuesday trading.

Price: 6.02, Change: +0.09, Percent Change: +1.60

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603636492?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 00:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603636492","market":"sg","top_or_hot":-1,"title":"Vir Biotechnology Reports Positive Data in Chronic Hepatitis Delta Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> (VIR) reported positive data from updated Phase 2 results in chronic hepatitis delta, showing that the combination of its investigational therapies tobevibart and elebsiran was well tolerated.</p><p>The company said Monday in a statement that 88% of patients had no detectable hepatitis D virus in their blood at 96 weeks.</p><p>Vir said it will present new Phase 1 data for VIR-5500, an experimental prostate-cancer therapy, at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in February.</p><p>The company ended 2025 with about $781 million in cash and investments, extending its cash runway into Q4 2027.</p><p>Vir said it expects multiple clinical milestones in 2026, including initial topline data from its Phase 3 chronic hepatitis delta program.</p><p>Vir shares rose 1.6% in recent Tuesday trading.</p><p>Price: 6.02, Change: +0.09, Percent Change: +1.60</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology Reports Positive Data in Chronic Hepatitis Delta Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology Reports Positive Data in Chronic Hepatitis Delta Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-14 00:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> (VIR) reported positive data from updated Phase 2 results in chronic hepatitis delta, showing that the combination of its investigational therapies tobevibart and elebsiran was well tolerated.</p><p>The company said Monday in a statement that 88% of patients had no detectable hepatitis D virus in their blood at 96 weeks.</p><p>Vir said it will present new Phase 1 data for VIR-5500, an experimental prostate-cancer therapy, at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in February.</p><p>The company ended 2025 with about $781 million in cash and investments, extending its cash runway into Q4 2027.</p><p>Vir said it expects multiple clinical milestones in 2026, including initial topline data from its Phase 3 chronic hepatitis delta program.</p><p>Vir shares rose 1.6% in recent Tuesday trading.</p><p>Price: 6.02, Change: +0.09, Percent Change: +1.60</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603636492","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603636492","pubTimestamp":1768321746,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vir Biotechnology  reported positive data from updated Phase 2 results in chronic hepatitis delta, showing that the combination of its investigational therapies tobevibart and elebsiran was well tolerated.The company said Monday in a statement that 88% of patients had no detectable hepatitis D virus in their blood at 96 weeks.Vir said it will present new Phase 1 data for VIR-5500, an experimental prostate-cancer therapy, at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in February.The company ended 2025 with about $781 million in cash and investments, extending its cash runway into Q4 2027.Vir said it expects multiple clinical milestones in 2026, including initial topline data from its Phase 3 chronic hepatitis delta program.Vir shares rose 1.6% in recent Tuesday trading.Price: 6.02, Change: +0.09, Percent Change: +1.60","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4568":"美国抗疫概念","VIR":"Vir Biotechnology, Inc.","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓"},"translate_title":"Vir Biotechnology报告慢性δ型肝炎试验阳性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Vir Biotechnology (VIR) reported positive data from updated Phase 2 results in chronic hepatitis delta, showing that the combination of its investigational therapies tobevibart and elebsiran was well tolerated.The company said Monday in a statement that 88% of patients had no detectable hepatitis D virus in their blood at 96 weeks.Vir said it will present new Phase 1 data for VIR-5500, an experimental prostate-cancer therapy, at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in February.The company ended 2025 with about $781 million in cash and investments, extending its cash runway into Q4 2027.Vir said it expects multiple clinical milestones in 2026, including initial topline data from its Phase 3 chronic hepatitis delta program.Vir shares rose 1.6% in recent Tuesday trading.Price: 6.02, Change: +0.09, Percent Change: +1.60","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603636492","isCrawlerRequest":true}